Skip to main content
Premium Trial:

Request an Annual Quote

Sylentis Aims to Begin Phase I Study of Glaucoma Drug in September

Premium

By Doug Macron

Spanish RNAi drug shop Sylentis expects to dose the first patient in a phase I study of its glaucoma-associated ocular hypertension drug SYL040012 in Spain around the end of September, a company official confirmed to RNAi News this week.

The disclosure comes about a month after the company announced that it had received clearance from Spanish regulators to begin the trial, in line with its previously disclosed guidance (see RNAi News, 2/19/2009).

SYL040012 is an siRNA targeted against adrenergic receptor beta-2 and has demonstrated the ability to both reduce intraocular pressure and prevent glaucoma in animal models, according to the company. The trial will examine the drug’s safety and tolerability in healthy volunteers.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.